This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weitman, S. Articles by Von Hoff, D. D. Search for Related Content PubMed PubMed Citation Articles by Weitman, S. Articles by Von Hoff, D. D.

The New Dioxolane, (-)-2'-Deoxy-3'-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts¹

The Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, Texas 78245 [S. W., J. M., D. D. V. H.]; The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 [S. W., D. D. V. H.]; and BioChem Pharma, Inc., Laval, Quebec, Canada H7V 4A7 [J. J., C. L.]

There is a great need for new therapeutic agents for patients with advanced pancreatic cancer. The new dioxolane analogue troxacitabine was evaluated in two human pancreatic cancer xenograft models. The models used included the Panc-01 and MiaPaCa pancreatic cancer cell lines. Whereas there is certainly no absolute evidence that either of the in vivo models is predictive for clinical activity, there is at least some evidence that they may be helpful in selecting agents for clinical trials in patients with pancreatic cancer. Troxacitabine was administered i.v. to the animals at doses of 10 and 25 mg/kg on a daily x 5 regimen. Gemcitabine was used as a positive control. The end points for the study included tumor growth inhibition (TGI), final weight, and the number of partial and complete tumor responses in the animals. Troxacitabine was highly active against the Panc-01 model (n = 8), with TGI levels of 88.5% and 84.3% at the 10 and 25 mg/kg doses, respectively. The mean final tumor weights for animals given troxacitabine were also significantly smaller (P < 0.001) compared with vehicle controls. At the 10 mg/kg dose, there were three partial tumor shrinkages and one complete tumor shrinkage, whereas at the 25 mg/kg dose, there were three partial tumor shrinkages. Troxacitabine had less activity against the MiaPaCa model (n = 10) and, by traditional response criteria, would be considered inactive, with TGIs of 4% and 22.7% at the 10 and 25 mg/kg dose level, respectively. Of note is that in comparison with gemcitabine, troxacitabine was more efficacious against Panc-01 and was equally active against MiaPaCa. These in vivo results are encouraging and support the prospect of performing Phase II and perhaps Phase III trials with troxacitabine in patients with advanced pancreatic cancer.

This article has been cited by other articles:

				C. K. K. Lee, E. K. Rowinsky, J. Li, F. Giles, M. J. Moore, M. Hidalgo, E. Capparelli, J. Jolivet, and S. D. Baker Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin. Cancer Res., April 1, 2006; 12(7): 2158 - 2165. [Abstract] [Full Text] [PDF]

				C.-H. Hsu, J.-Y. Liou, G. E. Dutschman, and Y.-C. Cheng Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium Mol. Pharmacol., March 1, 2005; 67(3): 806 - 814. [Abstract] [Full Text] [PDF]

				R. Lapointe, R. Letourneau, W. Steward, R. E. Hawkins, G. Batist, M. Vincent, R. Whittom, M. Eatock, J. Jolivet, and M. Moore Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: Gastrointestinal tumors Ann. Onc., February 1, 2005; 16(2): 289 - 293. [Abstract] [Full Text] [PDF]

				H. Gourdeau, L. Leblond, B. Hamelin, K. Dong, F. Ouellet, C. Boudreau, D. Custeau, A. Richard, M.-J. Gilbert, and J. Jolivet Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics: Implications for Clinical Development Clin. Cancer Res., November 15, 2004; 10(22): 7692 - 7702. [Abstract] [Full Text] [PDF]

				T. E. Kim, S.-Y. Park, C.-H. Hsu, G. E. Dutschman, and Y.-C. Cheng Synergistic Antitumor Activity of Troxacitabine and Camptothecin in Selected Human Cancer Cell Lines Mol. Pharmacol., August 1, 2004; 66(2): 285 - 292. [Abstract] [Full Text] [PDF]

				C.A. Townsley, K. Chi, D.S. Ernst, K. Belanger, I. Tannock, G.A. Bjarnason, D. Stewart, R. Goel, J.D. Ruether, L.L. Siu, et al. Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group J. Clin. Oncol., April 15, 2003; 21(8): 1524 - 1529. [Abstract] [Full Text] [PDF]

				S. McKenna and M. Eatock The Medical Management of Pancreatic Cancer: A Review Oncologist, April 1, 2003; 8(2): 149 - 160. [Abstract] [Full Text] [PDF]

				F. J. Giles, S. Faderl, D. A. Thomas, J. E. Cortes, G. Garcia-Manero, D. Douer, A. M. Levine, C. A. Koller, S. S. Jeha, S. M. O'Brien, et al. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias J. Clin. Oncol., March 15, 2003; 21(6): 1050 - 1056. [Abstract] [Full Text] [PDF]

				J.-Y. Liou, G. E. Dutschman, W. Lam, Z. Jiang, and Y.-C. Cheng Characterization of Human UMP/CMP Kinase and Its Phosphorylation of D- and L-Form Deoxycytidine Analogue Monophosphates Cancer Res., March 1, 2002; 62(6): 1624 - 1631. [Abstract] [Full Text] [PDF]

				J. S. de Bono, J. Stephenson Jr, S. D. Baker, M. Hidalgo, A. Patnaik, L. A. Hammond, G. Weiss, A. Goetz, L. Siu, C. Simmons, et al. Troxacitabine, an L-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies J. Clin. Oncol., January 1, 2002; 20(1): 96 - 109. [Abstract] [Full Text] [PDF]

				H. Gourdeau, M. L. Clarke, F. Ouellet, D. Mowles, M. Selner, A. Richard, N. Lee, J. R. Mackey, J. D. Young, J. Jolivet, et al. Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines Cancer Res., October 1, 2001; 61(19): 7217 - 7224. [Abstract] [Full Text] [PDF]